The Baltimore Pediatric AIDS Clinical Trials Group (PACTG) reflects a long-standing collaborative effort between the Departments of Pediatrics of Johns Hopkins University (JHU) School of Medicine and the University of Maryland Baltimore (UMB). Established in 1988, the Baltimore PACTG has provided HIV-infected children and pregnant women in Baltimore and throughout the state of Maryland with access to clinical trials. More than 500 women and children have been enrolled in PACTG trials since the inception of the Unit. Over 300 perinatally HIV infected children are currently in active clinical follow-up at the two sites, as well as 60 HIV infected adolescents whose risk factors are limited to sexual and drug use exposure. Approximately 50 HIV infected women deliver per year at the two hospitals. This collaborative effort has brought together investigators with considerable scientific expertise in the areas of clinical trials, perinatal HIV transmission, medication adherence and HIV virology. Baltimore PACTU investigators have participated actively in PACTG leadership roles, currently serving on 10 PACTG committees/protocols. In addition, the two units have developed a broad range of international collaborations with mid-level and developing countries, both through independent research funding, as well as through the Fogarty AIDS International Training and Research Program (AITRP), HIV Prevention Trials Network (HPTN) and HIV Vaccine Trial Network (HVTN). In this submission, we have strengthened our adolescent component, adding investigators with strong track records in both the science and conduct of research among adolescents, including a newly funded Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN). With our existing infrastructure and broad scientific expertise, we anticipate continuing to enroll participants into a variety of protocols and making substantial contributions to the PACTG scientific agenda.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Matula, Margaret A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Lambert, John S; Moye Jr, Jack; Plaeger, Susan F et al. (2005) Association of selected phenotypic markers of lymphocyte activation and differentiation with perinatal human immunodeficiency virus transmission and infant infection. Clin Diagn Lab Immunol 12:622-31
Watts, D Heather; Lambert, John; Stiehm, E Richard et al. (2003) Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr 33:585-93
Lambert, John S; Harris, D Robert; Stiehm, E Richard et al. (2003) Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection. J Acquir Immune Defic Syndr 34:512-9
Lambert, J S; Watts, D H; Mofenson, L et al. (2000) Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team. AIDS 14:1389-99
Henderson, R A; Talusan, K; Hutton, N et al. (1999) Whole body protein turnover in children with human immunodeficiency virus (HIV) infection. Nutrition 15:189-94
Stiehm, E R; Lambert, J S; Mofenson, L M et al. (1999) Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis 179:567-75
Henderson, R A; Talusan, K; Hutton, N et al. (1998) Resting energy expenditure and body composition in children with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 19:150-7
Lambert, J S; Viscidi, R; Walker, M C et al. (1997) Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Clin Diagn Lab Immunol 4:302-8
Lambert, J S; Mofenson, L M; Fletcher, C V et al. (1997) Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. J Infect Dis 175:283-91
Henderson, R A; Talusan, K; Hutton, N et al. (1997) Serum and plasma markers of nutritional status in children infected with the human immunodeficiency virus. J Am Diet Assoc 97:1377-81

Showing the most recent 10 out of 20 publications